|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Nociceptive Pain - Safety Profile Uppermost in Crowded Market
Datamonitor, Oct 2004, Pages: 264
Introduction
The nociceptive pain pipeline contains few novel drugs, instead being filled with reformulations and drug combinations. To make a drug stand out in this replete market, particularly at a time when there is great public concern about drug withdrawals, it must have an unquestionable safety profile, proven over long-term trials.
Scope
Epidemiology of nociceptive pain across the seven major markets, as well as analysis of the main unmet needs in the current treatment of the disease
Overview of drugs in Phase III, II, I and preclinical development, plus analysis of key companies involved in the R&D pipeline: GSK, Merck and Endo
Comprehensive analysis of key late-stage products including DepoDur, Ionsys, Prexige, Prialt & THC monotherapy, with drug revenues forecast to 2014
Insight into innovative early stage products, including vanilloid and Bradykinin receptors, plus analysis of key research into gene therapy for pain
Highlights
Although pain is not a new phenomenon, better education for patients, physicians, nurses and pharmacists is still an unmet need. The current range of therapies should be sufficient for pain relief if used knowledgably.
New COX-2 inhibiting drugs will have to provide impeccable safety data from long-term trials before gaining approval in the current climate where the whole class of drugs is suspect. If safety can be proved, the market is relatively small, and new entrants may do well.
While experts believe morphine is still the most effective painkiller available, it can be improved upon in terms of convenience and side effects. Many opioids in development are reformulations of old drugssustained release, or patch deliveryor receptor-specific drugs aiming to reduce side effects.
Reasons to Purchase
Enhance your sales forecasting ability and future product positioning through identification of market drivers and key competitors
Optimize your knowledge of company strategies in the nociceptive pain market
Identify areas of the market that are not being targeted by competitors
Customers who bought this item also bought
Pain Therapeutics - Drugs, Markets and Companies
US Cancer Pain Report
Back Pain Report 2008
Drugs of Tommorrow 2002: Pain
Pipeline Insight: Neuropathic Pain - Emerging Drugs Fail to Capitalize in Lucrative Market
The Pain Management Market Outlook To 2014: Competitive Landscape, Pipeline Analysis and Growth Opportunities
Pipeline Insight: Neuropathic Pain - Pipeline Drugs Fail To Nail Neuropathic Pain
Commercial Insight: Pain Market Overview - Non-traditional Analgesics and Opioid Reformulations to Sustain Sector Growth
Pain Management - Global Strategic Business Report
The Global Pain Therapeutics Market, 3rd Edition - Market Analysis, R&D Pipelines and Competitive Landscape
The Pain Market Outlook to 2011
The Global Pain Therapeutics Market: Market Analysis, R&D Pipelines and Competitive Landscape
|
|
|
|
